Skip to main content

Pacritinib

Details of the Drug
Generic Name:
Pacritinib
Drug Type:
Kinase inhibitor
How the Drug is Given:

Capsules, for oral use

Names:
Vonjo™
Pacritinib

Indications and Usage

Pacritinib is indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L.

This indication is approved under accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
 

Side effects needing medical attention

The most common adverse reactions are diarrhea, thrombocytopenia, nausea, anemia, and peripheral edema.

For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.